<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071096</url>
  </required_header>
  <id_info>
    <org_study_id>10-001AL</org_study_id>
    <nct_id>NCT01071096</nct_id>
  </id_info>
  <brief_title>Calcitonin Gene-related Peptide Levels in Chronic Migraine</brief_title>
  <official_title>Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to
      evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP)
      levels in saliva following treatment with OnabotulinumtoxinA versus saline.

      Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline
      at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over
      injections at Visit 5.

      Patients will return for monthly visits and exit the study at Visit 8.

      Patients will collect saliva at monthly intervals and document in a daily headache diary
      throughout the study .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind study will evaluate reduction in number of headache days following
      treatment with OnabotulinumtoxinA versus Saline. Additionally, CGRP levels in saliva will be
      correlated with a reduction in headache attacks.

      At Visit 1, eligible subjects will be randomized 1:1 to receive injections of
      OnabotulinumtoxinA or Saline in an identical manner. Subjects will collect 3 saliva samples
      during each month of the 7 month study: 1 collection at Baseline headache level, 1 collection
      at onset of headache that is one degree worse than Baseline level that will be treated with
      acute therapy, and 1 collection at 2 hours following treatment. Subjects will document
      headache and headache symptoms in a daily diary and return to the clinic with diary and
      saliva samples at monthly visits.

      Following 4 months (including a 1 month washout after Visit 4), subjects will return at Visit
      5 and receive cross-over injections. Subjects randomized to OnabotulinumtoxinA at Visit 1
      will receive injections of Saline. Subjects randomized to saline at Visit 1 will receive
      injections of OnabotulinumtoxinA. Subjects will document headache and headache symptoms in a
      daily diary and return to the clinic with diary and saliva samples at monthly visits.

      At Visit 8, 3 months following re-injection at Visit 5, subjects will exit the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.</measure>
    <time_frame>Baseline (collected historically at screening) versus (vs.) Month (Mo) 1, Mo 2, Mo 3, Mo 4, Mo 5, Mo 6, and Mo 7</time_frame>
    <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).</measure>
    <time_frame>Baseline (collected historically at screening) vs. Mo 1, Mo 1 vs. Mo 2, Mo 2 vs. Mo 3, Mo 3 vs. Mo 4, Mo 4 vs. Mo 5, Mo 5 vs. Mo 6, and Mo 6 vs. Mo 7</time_frame>
    <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)</measure>
    <time_frame>Baseline levels collected for OnabotulinumtoxinA and Saline treatment during Months 1 through 7</time_frame>
    <description>CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva CGRP Levels for OnabotulinumtoxinA Responders (Reduction of Headache Days Greater Than 30%) vs. Non-responders and Saline</measure>
    <time_frame>For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3</time_frame>
    <description>Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Between Inter-ictal (Baseline) Levels Between Responders and Non-responders</measure>
    <time_frame>For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3 at Baseline level (inter-ictal) and at onset of headache that is one degree worse than Baseline level and that will be treated with acute therapy</time_frame>
    <description>Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, &amp; 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm.</description>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <other_name>Botulinum Toxin Type A Purified Neurotoxin Complex</other_name>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be outpatient, male or female, of any race, between 18 and 65 years of age.

          -  if female of childbearing potential must have negative pregnancy test result at
             Screening Visit and practice reliable method of contraception.

        A female is considered of childbearing potential unless she is post menopausal for at least
        12 months prior to administration of study drug, without a uterus and/or both ovaries or
        has been surgically sterilized for at least 6 months prior to study drug administration.

        Reliable methods of contraception are: Complete abstinence from intercourse from 2 weeks
        prior to administration of the investigational product, throughout the study, and for a
        time interval (5 days) after completion or premature discontinuation from the study; or,
        History of bilateral tubal ligation; or, Sterilization of male partner; or, Implants of
        levonorgestrel; or, Injectable progestogen; or, Oral contraceptive (combination therapy
        with ethinyl estradiol plus a progestin) with a placebo week every 1-3 months; or, Any
        intrauterine device (IUD) with published data showing that the highest expected failure
        rate is less than 1% per year (not all IUD's meet this criterion) in use at least 30 days
        prior to study drug administration; or, Spermicide plus a mechanical barrier (e.g.,
        spermicide plus a male condom or a female diaphragm); or, Any other barrier methods (only
        is used in combination with any of the above acceptable methods) in use at least 14 days
        prior to study drug administration; or, Any other methods with published data showing that
        the highest expected failure rate for that methods is less than 1% per year.

          -  must have history of chronic migraine (with or without aura) according to the criteria
             proposed by the Headache Classification Committee of the International Headache
             Society (IHS) for at least 3 months prior to enrollment.

          -  must be able to understand the requirements of the study including maintaining a
             headache Diary, and signing informed consent.

          -  must be in good general health as determined by investigator.

          -  if taking migraine preventive, must be on a stable dose of preventive medication for
             at least 3 months prior to screening.

        Exclusion Criteria:

          -  if female, is pregnant, planning to become pregnant during the study period, is breast
             feeding, or is of childbearing potential and not practicing a reliable form of birth
             control.

          -  has headache disorders outside IHS-defined chronic migraine definition.

          -  has evidence of underlying pathology contributing to their headaches.

          -  has any pathology of the salivary glands such as sialadenitis (e.g. Sjogren's
             syndrome, viral or bacterial sialadenitis) or condition or symptom that would alter
             the content of saliva.

          -  has any medical condition that may increase their risk with exposure to
             OnabotulinumtoxinA including diagnosed myasthenia gravis, Eaton-Lambert syndrome,
             amyotrophic lateral sclerosis, or any other significant disease that might interfere
             with neuromuscular function.

          -  has profound atrophy or weakness of muscles in the target areas of injection.

          -  has skin conditions or infections at any of the injection sites.

          -  has allergy or sensitivities to any component of the test medication.

          -  who in the opinion of the investigator, has active major psychiatric or depressive
             disorders including alcohol/drug abuse.

          -  meets International Headache Society criteria for Medication Overuse with opioid or
             butalbital containing products.

          -  is planning or requiring surgery during the study.

          -  has a history of poor compliance with medical treatment.

          -  is currently participating in an investigational drug study or has participated in an
             investigational drug study within the previous 30 days of the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neurological Associates, P.C.</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache. 2006 Jan;46(1):24-33.</citation>
    <PMID>16412148</PMID>
  </reference>
  <reference>
    <citation>Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009 Oct;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.x.</citation>
    <PMID>19788468</PMID>
  </reference>
  <reference>
    <citation>Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 Jan;44(1):35-42; discussion 42-3.</citation>
    <PMID>14979881</PMID>
  </reference>
  <reference>
    <citation>Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci. 2007 Jul-Aug;11(4):245-8. Review.</citation>
    <PMID>17876959</PMID>
  </reference>
  <reference>
    <citation>Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, Bussone G, Toso V. Plasma cytokine levels in migraineurs and controls. Headache. 2005 Jul-Aug;45(7):926-31.</citation>
    <PMID>15985111</PMID>
  </reference>
  <reference>
    <citation>Sarchielli P, Alberti A, Vaianella L, Pierguidi L, Floridi A, Mazzotta G, Floridi A, Gallai V. Chemokine levels in the jugular venous blood of migraine without aura patients during attacks. Headache. 2004 Nov-Dec;44(10):961-8.</citation>
    <PMID>15546258</PMID>
  </reference>
  <reference>
    <citation>Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache. 2001 Sep;41(8):764-7.</citation>
    <PMID>11576199</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>January 16, 2012</results_first_submitted>
  <results_first_submitted_qc>January 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2012</results_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Botox</keyword>
  <keyword>OnabotulinumtoxinA</keyword>
  <keyword>Chronic Migraine</keyword>
  <keyword>Calcitonin Gene-Related Peptide</keyword>
  <keyword>Saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Subjects were injected with OnabotulinumtoxinA at Visit 1 (Day 1) and followed for 3 months through monthly office visits (Visits 2, 3, and 4 at Days 31, 61 and 91). Subjects went through a 1 month (30 day) washout period between Visit 4 (Day 91) and Visit 5 (Day 121). Subjects were injected with Saline at Visit 5 (Day 121) and followed for 3 months through monthly office visits (Visits 5, 6, and 7 at Days 151, 181, and 211).</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Subjects were injected with Saline at Visit 1 (Day 1) and followed for 3 months through monthly office visits (Visits 2, 3, and 4 at Days 31, 61 and 91). Subjects went through a 1 month (30 day) washout period between Visit 4 (Day 91) and Visit 5 (Day 121). Subjects were injected with OnabotulinumtoxinA at Visit 5 (Day 121) and followed for 3 months through monthly office visits (Visits 5, 6, and 7 at Days 151, 181, and 211).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (90 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (30 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (90 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Participants</title>
          <description>Enrolled Participants includes subjects in both Group A (treated with BOTOX and Visit 1 and Placebo at Visit 5) and Group B (treated with Placebo at Visit 1 and BOTOX at Visit 5).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.45" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.</title>
        <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
        <time_frame>Baseline (collected historically at screening) versus (vs.) Month (Mo) 1, Mo 2, Mo 3, Mo 4, Mo 5, Mo 6, and Mo 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>OnabotulinumtoxinA at Visit 1 (headache days in Months 1, 2 and 3) and Saline at Visit 5 (headache days in Months 5, 6 and 7) with washout and crossover at Month 4</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Saline at Visit 1 (headache days in Months 1, 2 and 3) and OnabotulinumtoxinA at Visit 5 (headache days in Months 5, 6 and 7) with washout and crossover at Month 4</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.</title>
          <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline vs. Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="8.01"/>
                    <measurement group_id="O2" value="-6.67" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.72" spread="5.96"/>
                    <measurement group_id="O2" value="-5.22" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.06" spread="5.92"/>
                    <measurement group_id="O2" value="-5.22" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.50" spread="8.34"/>
                    <measurement group_id="O2" value="-6.89" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.94" spread="8.15"/>
                    <measurement group_id="O2" value="-6.33" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.50" spread="7.93"/>
                    <measurement group_id="O2" value="-9.22" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline vs. Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="7.53"/>
                    <measurement group_id="O2" value="-4.56" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).</title>
        <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
        <time_frame>Baseline (collected historically at screening) vs. Mo 1, Mo 1 vs. Mo 2, Mo 2 vs. Mo 3, Mo 3 vs. Mo 4, Mo 4 vs. Mo 5, Mo 5 vs. Mo 6, and Mo 6 vs. Mo 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>OnabotulinumtoxinA at Visit 1 (headache days in Months 1, 2 and 3) and Saline at Visit 5 (headache days in Months 5, 6 and 7) with washout and crossover at Month 4</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Saline at Visit 1 (headache days in Months 1, 2 and 3) and OnabotulinumtoxinA at Visit 5 (headache days in Months 5, 6 and 7) with washout and crossover at Month 4</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).</title>
          <description>Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline vs. Mo 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="8.01"/>
                    <measurement group_id="O2" value="-6.67" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 1 vs. Mo 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="7.20"/>
                    <measurement group_id="O2" value="1.44" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 2 vs. Mo 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="3.97"/>
                    <measurement group_id="O2" value="0.00" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 3 vs. Mo 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="3.91"/>
                    <measurement group_id="O2" value="-1.67" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 4 vs. Mo 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="3.21"/>
                    <measurement group_id="O2" value="0.56" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 5 vs. Mo 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="3.84"/>
                    <measurement group_id="O2" value="-2.89" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mo 6 vs. M 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="3.84"/>
                    <measurement group_id="O2" value="4.67" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)</title>
        <description>CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month.</description>
        <time_frame>Baseline levels collected for OnabotulinumtoxinA and Saline treatment during Months 1 through 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA</title>
            <description>This group is a combination of information gathered from both groups while treating with OnabotulinumtoxinA: Group A (Months 1-3) and Group B (Months 5-7).</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>This group is a combination of information gathered from both groups while treating with Saline: Group A (Months 5-7) and Group B (Months 1-3).</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)</title>
          <description>CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month.</description>
          <units>pmol/mg total protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.64" spread="7.5"/>
                    <measurement group_id="O2" value="40.79" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.37" spread="7.07"/>
                    <measurement group_id="O2" value="39.14" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.14" spread="3.93"/>
                    <measurement group_id="O2" value="50.63" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saliva CGRP Levels for OnabotulinumtoxinA Responders (Reduction of Headache Days Greater Than 30%) vs. Non-responders and Saline</title>
        <description>Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication.</description>
        <time_frame>For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA Responders</title>
            <description>This group is a combination of information gathered from both groups while treating with OnabotulinumtoxinA: Group A (Months 1-3) and Group B (Months 5-7). Includes subjects with &gt;30% reduction in number of headache days per month when compared to Baseline</description>
          </group>
          <group group_id="O2">
            <title>OnabotulinumtoxinA Non-Responders</title>
            <description>This group is a combination of information gathered from both groups while treating with OnabotulinumtoxinA: Group A (Months 1-3) and Group B (Months 5-7). Includes subjects with &lt;30% reduction in number of headache days per month when compared to Baseline</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>This group is a combination of information gathered from both groups while treating with Saline: Group A (Months 5-7) and Group B (Months 1-3).</description>
          </group>
        </group_list>
        <measure>
          <title>Saliva CGRP Levels for OnabotulinumtoxinA Responders (Reduction of Headache Days Greater Than 30%) vs. Non-responders and Saline</title>
          <description>Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication.</description>
          <units>pmol/mg total protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Month 1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.36" spread="56.31"/>
                    <measurement group_id="O2" value="29.36" spread="32.81"/>
                    <measurement group_id="O3" value="70.46" spread="98.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 1 - Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.94" spread="21.85"/>
                    <measurement group_id="O2" value="22.36" spread="20.38"/>
                    <measurement group_id="O3" value="36.23" spread="33.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 1 - 2 Hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.55" spread="44.82"/>
                    <measurement group_id="O2" value="23.66" spread="12.11"/>
                    <measurement group_id="O3" value="39.76" spread="54.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.89" spread="49.27"/>
                    <measurement group_id="O2" value="28.66" spread="20.59"/>
                    <measurement group_id="O3" value="44.12" spread="49.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 2 - Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.14" spread="51.18"/>
                    <measurement group_id="O2" value="32.65" spread="33.80"/>
                    <measurement group_id="O3" value="33.05" spread="30.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 2 - 2 Hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.13" spread="60.98"/>
                    <measurement group_id="O2" value="22.35" spread="19.94"/>
                    <measurement group_id="O3" value="33.93" spread="35.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 3 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.33" spread="77.44"/>
                    <measurement group_id="O2" value="32.61" spread="40.13"/>
                    <measurement group_id="O3" value="58.74" spread="53.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 3 - Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.18" spread="58.88"/>
                    <measurement group_id="O2" value="30.17" spread="38.63"/>
                    <measurement group_id="O3" value="46.16" spread="40.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month 3 - 2 Hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.04" spread="34.77"/>
                    <measurement group_id="O2" value="19.11" spread="13.24"/>
                    <measurement group_id="O3" value="49.39" spread="43.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Between Inter-ictal (Baseline) Levels Between Responders and Non-responders</title>
        <description>Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, &amp; 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES)</description>
        <time_frame>For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3 at Baseline level (inter-ictal) and at onset of headache that is one degree worse than Baseline level and that will be treated with acute therapy</time_frame>
        <population>Number of Participants Analyzed is low due to some unusable samples and missing samples making comparison between months impossible. 5 Responders and 5 Non-Responders provided enough samples at all time points for comparisons.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 1 vs. Saline Responders</title>
            <description>Fold change between first treatment months with OnabotulinumtoxinA and Saline in subjects with &gt;30% reduction in number of headache days per month from baseline.</description>
          </group>
          <group group_id="O2">
            <title>Month 1 vs. Saline Non-Responders</title>
            <description>Fold change between first treatment months with OnabotulinumtoxinA and Saline in subjects with &lt;30% reduction in number of headache days per month from baseline.</description>
          </group>
          <group group_id="O3">
            <title>Month 3 vs. Saline Responders</title>
            <description>Fold change between third treatment months with OnabotulinumtoxinA and Saline in subjects with &gt;30% reduction in number of headache days per month from baseline.</description>
          </group>
          <group group_id="O4">
            <title>Month 3 vs. Saline Non-Responders</title>
            <description>Fold change between third treatment months with OnabotulinumtoxinA and Saline in subjects with &lt;30% reduction in number of headache days per month from baseline.</description>
          </group>
          <group group_id="O5">
            <title>Month 1 vs. Month 3 Responders</title>
            <description>Fold change between first and third treatment months with OnabotulinumtoxinA in subjects with &gt;30% reduction in number of headache days per month from baseline.</description>
          </group>
          <group group_id="O6">
            <title>Month 1 vs. Month 3 Non-Responders</title>
            <description>Fold change between first and third treatment months with OnabotulinumtoxinA in subjects with &lt;30% reduction in number of headache days per month from baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Between Inter-ictal (Baseline) Levels Between Responders and Non-responders</title>
          <description>Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, &amp; 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES)</description>
          <population>Number of Participants Analyzed is low due to some unusable samples and missing samples making comparison between months impossible. 5 Responders and 5 Non-Responders provided enough samples at all time points for comparisons.</population>
          <units>Florescent Units (FU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C5/C5a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.23"/>
                    <measurement group_id="O2" value="1.01" spread="0.90"/>
                    <measurement group_id="O3" value="1.39" spread="0.80"/>
                    <measurement group_id="O4" value="1.61" spread="0.54"/>
                    <measurement group_id="O5" value="1.03" spread="0.57"/>
                    <measurement group_id="O6" value="3.26" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40 Ligand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.25"/>
                    <measurement group_id="O2" value="1.26" spread="0.99"/>
                    <measurement group_id="O3" value="0.98" spread="0.37"/>
                    <measurement group_id="O4" value="1.31" spread="0.63"/>
                    <measurement group_id="O5" value="0.91" spread="0.27"/>
                    <measurement group_id="O6" value="1.22" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.45"/>
                    <measurement group_id="O2" value="0.93" spread="0.55"/>
                    <measurement group_id="O3" value="0.85" spread="0.24"/>
                    <measurement group_id="O4" value="0.99" spread="0.58"/>
                    <measurement group_id="O5" value="1.07" spread="0.74"/>
                    <measurement group_id="O6" value="1.34" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GROa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.56"/>
                    <measurement group_id="O2" value="3.18" spread="2.20"/>
                    <measurement group_id="O3" value="1.40" spread="1.33"/>
                    <measurement group_id="O4" value="1.81" spread="1.32"/>
                    <measurement group_id="O5" value="1.05" spread="0.96"/>
                    <measurement group_id="O6" value="0.73" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="2.32"/>
                    <measurement group_id="O2" value="0.61" spread="0.54"/>
                    <measurement group_id="O3" value="5.99" spread="6.13"/>
                    <measurement group_id="O4" value="2.00" spread="1.98"/>
                    <measurement group_id="O5" value="3.99" spread="3.22"/>
                    <measurement group_id="O6" value="1.51" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.34"/>
                    <measurement group_id="O2" value="0.80" spread="0.69"/>
                    <measurement group_id="O3" value="1.29" spread="0.82"/>
                    <measurement group_id="O4" value="1.92" spread="2.95"/>
                    <measurement group_id="O5" value="0.91" spread="0.34"/>
                    <measurement group_id="O6" value="1.63" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="1.86"/>
                    <measurement group_id="O2" value="2.88" spread="4.29"/>
                    <measurement group_id="O3" value="1.50" spread="0.92"/>
                    <measurement group_id="O4" value="2.14" spread="3.04"/>
                    <measurement group_id="O5" value="0.86" spread="0.60"/>
                    <measurement group_id="O6" value="0.81" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.80"/>
                    <measurement group_id="O2" value="1.12" spread="1.09"/>
                    <measurement group_id="O3" value="1.38" spread="1.15"/>
                    <measurement group_id="O4" value="0.51" spread="0.23"/>
                    <measurement group_id="O5" value="1.15" spread="0.12"/>
                    <measurement group_id="O6" value="1.03" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.56"/>
                    <measurement group_id="O2" value="2.02" spread="2.66"/>
                    <measurement group_id="O3" value="0.96" spread="0.39"/>
                    <measurement group_id="O4" value="1.90" spread="1.58"/>
                    <measurement group_id="O5" value="0.88" spread="0.12"/>
                    <measurement group_id="O6" value="1.30" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.83"/>
                    <measurement group_id="O2" value="1.70" spread="2.03"/>
                    <measurement group_id="O3" value="2.71" spread="2.29"/>
                    <measurement group_id="O4" value="1.22" spread="1.24"/>
                    <measurement group_id="O5" value="4.38" spread="6.98"/>
                    <measurement group_id="O6" value="2.28">Only one value available (2.28) so there is no standard deviation between reported values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.63"/>
                    <measurement group_id="O2" value="2.07" spread="1.63"/>
                    <measurement group_id="O3" value="0.75" spread="0.48"/>
                    <measurement group_id="O4" value="1.97" spread="1.64"/>
                    <measurement group_id="O5" value="0.98" spread="0.66"/>
                    <measurement group_id="O6" value="1.10" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.50"/>
                    <measurement group_id="O2" value="1.02" spread="0.91"/>
                    <measurement group_id="O3" value="1.59" spread="1.79"/>
                    <measurement group_id="O4" value="0.42" spread="0.13"/>
                    <measurement group_id="O5" value="1.28" spread="0.85"/>
                    <measurement group_id="O6" value="1.45" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="1.85"/>
                    <measurement group_id="O2" value="1.80" spread="1.55"/>
                    <measurement group_id="O3" value="1.06" spread="0.12"/>
                    <measurement group_id="O4" value="1.69" spread="1.54"/>
                    <measurement group_id="O5" value="0.93" spread="0.01"/>
                    <measurement group_id="O6" value="2.61" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.05"/>
                    <measurement group_id="O2" value="0.95" spread="0.17"/>
                    <measurement group_id="O3" value="0.86" spread="0.52"/>
                    <measurement group_id="O4" value="2.76" spread="2.23"/>
                    <measurement group_id="O5" value="1.55" spread="1.50"/>
                    <measurement group_id="O6" value="3.11" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I-TAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.78"/>
                    <measurement group_id="O2" value="0.28" spread="0.12"/>
                    <measurement group_id="O3" value="1.01" spread="0.89"/>
                    <measurement group_id="O4" value="0.94" spread="0.26"/>
                    <measurement group_id="O5" value="0.67" spread="0.27"/>
                    <measurement group_id="O6" value="3.65" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="6.25"/>
                    <measurement group_id="O2" value="9.55" spread="19.47"/>
                    <measurement group_id="O3" value="2.71" spread="4.50"/>
                    <measurement group_id="O4" value="8.66" spread="16.79"/>
                    <measurement group_id="O5" value="0.80" spread="0.32"/>
                    <measurement group_id="O6" value="1.24" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin E1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.17"/>
                    <measurement group_id="O2" value="0.70" spread="0.53"/>
                    <measurement group_id="O3" value="0.70" spread="0.33"/>
                    <measurement group_id="O4" value="0.90" spread="0.82"/>
                    <measurement group_id="O5" value="0.76" spread="0.39"/>
                    <measurement group_id="O6" value="3.16" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RANTES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.41"/>
                    <measurement group_id="O2" value="0.77" spread="0.28"/>
                    <measurement group_id="O3" value="0.93" spread="0.41"/>
                    <measurement group_id="O4" value="0.91" spread="0.27"/>
                    <measurement group_id="O5" value="1.14" spread="0.21"/>
                    <measurement group_id="O6" value="1.24" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>Subjects injected with Saline in Group A at Visit 5 (Day 151) and Group B at Visit 1 (Day 1)</description>
        </group>
        <group group_id="E2">
          <title>OnabotulinumtoxinA</title>
          <description>Subjects injected with onabotulinumtoxinA in Group A at Visit 1 (Day 1) and Group B at Visit 5 (Day 151)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion of extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Cholesterol</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Enlarged Lymph Node</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heart Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner Ear Fluid Imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Parotid Glad Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Salivary Gland Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Salivary Gland Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Scalp Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eyebrow Ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paresthesia as Injection Site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Track Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>1st Degree Burn on Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>2nd Degree Burn on Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Facial Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental Implant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ruptured Breast Implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to identified lab errors related to processing of samples for CGRP and cytokine levels, samples are currently being re-processed. Results will be posted following re-analysis of all study data related to sample values.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeanne Tarrasch</name_or_title>
      <organization>Clinvest</organization>
      <phone>417-841-3673</phone>
      <email>jtarrasch@clinvest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

